Provided by Tiger Trade Technology Pte. Ltd.

Quince Therapeutics, Inc.

31.73
+2.378.07%
Post-market: 31.730.00000.00%19:40 EDT
Volume:138.74K
Turnover:4.63M
Market Cap:32.27M
PE:-0.35
High:37.00
Open:30.50
Low:29.84
Close:29.36
52wk High:909.98
52wk Low:15.10
Shares:1.02M
Float Shares:679.70K
Volume Ratio:4.26
T/O Rate:20.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-90.9250
EPS(LYR):-335.2669
ROE:-153.84%
ROA:-31.51%
PB:-0.91
PE(LYR):-0.09

Loading ...

Quince Therapeutics Changes Name to IRulya Therapeutics

MT Newswires Live
·
Oct 09

Quince Therapeutics - Appoints Brigette Roberts as CEO Effective October 8, 2026 - SEC Filing

THOMSON REUTERS
·
Oct 09

Quince Therapeutics - Common Stock to Trade Under Symbol 'Irla' on NASDAQ Effective Oct 12, 2026

THOMSON REUTERS
·
Oct 09

Quince Therapeutics - Changes Name to Irulya Therapeutics

THOMSON REUTERS
·
Oct 09

Quince Therapeutics Appoints Brigette Roberts CEO in Management Overhaul

Reuters
·
Oct 09

Quince Therapeutics Holds Special Shareholder Meeting

Reuters
·
Oct 07

Quince Therapeutics Names Leone Patterson Audit, Compensation Committee Chair in Board Overhaul

Reuters
·
Oct 02

Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)

TIPRANKS
·
Sep 30

Quince Therapeutics to Host Virtual KOL Event on PH-ILD, BOS Treatment Landscape and LAM-001

Reuters
·
Sep 17

Quince Therapeutics Flags NASDAQ Noncompliance After Stockholders’ Equity Falls to ($35.32 Million)

Reuters
·
Sep 04

Quince Therapeutics President Charles Ryan to Exit Sept. 8

Reuters
·
Aug 28

Quince Therapeutics Announces Special Shareholder Meeting

Reuters
·
Aug 25

Craig-Hallum bullish on Quince Therapeutics, initiates with a Buy

TIPRANKS
·
Aug 20

Quince Therapeutics : Leerink Partners Adjusts Target Price to $68 from $4 to Reflect 1-for-20 Reverse Stock Split

THOMSON REUTERS
·
Aug 18

Quince Therapeutics Raises USD 115 Million in Private Placement of Series C Preferred Shares

Reuters
·
Aug 17

Quince Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Quince Therapeutics Q2 Net Loss Widens on Acquisition Charges

Reuters
·
Aug 14

Press Release: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Dow Jones
·
Aug 14

Quince Therapeutics, Inc. Expected to Post a Loss of $17.88 a Share - Earnings Preview

Reuters
·
Aug 07

Quince Therapeutics - Brigette Roberts Conditionally Appointed as Chief Executive Officer - SEC Filing

THOMSON REUTERS
·
Aug 01